Stryker Corp (SYK)
合理估值基本面
74
价格
$273.71
市值
$105.60B
第一部分 · 这家公司值多少
概览
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 61 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
资产负债表与流动性
营收
$25.84B
最近12个月（截至2026/6/30）
净利润
$3.73B
最近12个月（截至2026/6/30）
自由现金流
$4.28B
股东权益合计
$22.42B
负债合计
$25.42B
流动比率
2.16
利息覆盖率
8.05
债务/EBITDA
2.43
每股收益
营收与净利润
自由现金流
收入构成
历史财务表
利润率变化
债务变化
债务负担有多重
增长一览表
增长 — 营业收入
公允价值估算
公允价值
$291.11
当前价格
$273.71
安全边际
+6.0%
公允价值区间
$193.37 - $388.85
所用估值方法之间的离散区间，并非经过统计校准的置信区间。
估算方法
估值指标
市盈率（P/E）
28.54
ROE
14.5%
市净率（P/B）
4.40
P/FCF
22.47
毛利率
65.0%
ROIC
9.6%
盈利能力雷达图
价值创造（经济护城河）
ROIC
9.6%
WACC
8.1%
ROIC − WACC
+1.5 pp
ROIC 超过资本成本：公司正在为股东创造价值。
基本面分析标准
通过（22）
- EPS shows upward trend
- EPS CAGR 7.11%
- Price CAGR 8.69%
- ROIC 9.6%
- Gross Margin 65.0%
- P/FCF 22.47
- Debt/Equity ratio
- Operating Margin 19.5%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- ROE 16.4%
- Revenue Growth 5Y 11.8%
- Analyst Consensus 79% Buy
- PEG Ratio 1.91
- Earnings Quality (OCF/NI) 1.48
- Share Dilution 0.2%
- Net Margin Trend 14.4% vs 12.3%
- Piotroski F-Score 5/9
未通过（5）
- P/B Ratio 4.40
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Earnings Surprise avg -1.9%
不可用（1）
- Dividend Payout NaN%
Piotroski F-评分
信号混杂：部分领域需关注
盈利质量
高质量：盈利有现金流支撑
股权稀释
股份数量稳定
机构持股
公司治理
管理团队
| 姓名 | 职位 | 年龄 |
|---|---|---|
| Mr. Kevin A. Lobo | Chairman & CEO | 60 |
| Mr. Spencer S. Stiles | President & COO | 48 |
| Mr. Preston W. Wells | VP & CFO | 48 |
| Mr. Viju S. Menon | Group President of Global Quality & Operations | 57 |
| Mr. J. Andrew Pierce | Group President of MedSurg & Neurotechnology | 51 |
| Ms. Emily Baculik | VP, Chief Accounting Officer & Corporate Controller | 45 |
| Mr. Robert C. Cohen | CTO and VP of Global R&D - Joint Replacement | - |
| Ms. Debra S. King | VP and Chief Digital & Information Officer | 53 |
| Mr. Nick Mead | Vice President of Investor Relations | - |
| Mr. Robert S. Fletcher | VP & Chief Legal Officer | 54 |
审计风险
10
董事会风险
9
薪酬风险
1
股东权利风险
6
第二部分 · 价格与买入时机
这一部分不判断公司是否值得拥有：它帮助你在基本面说服你之后，选择何时买入。包含：技术分析、潜力、历史回撤、Gamma 敞口。
损益历史
via SEC EDGAR
Latest News
Recent headlines for SYK, sourced from Markets Gazette.